Live price temporarily unavailable.
Tenax Therapeutics (TENX) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | — | — | — | — | — | — | — | $0 | $0 |
| Growth (year over year) | −100.0% | — | — | — | — | — | — | — | — | — |
| Gross profit | $0 | — | — | — | — | — | — | — | — | — |
| Operating income | −$52.7M | −$9.21M | −$6.89M | −$8.56M | $9.87M | −$32.7M | $11.1M | −$8.23M | −$19.5M | −$56.4M |
| Net income | −$43.9M | −$8.84M | −$14.1M | −$8.39M | −$9.85M | −$32.5M | $11.0M | −$7.71M | −$17.6M | −$52.6M |
| EPS (diluted) | −$31.24 | −$6.27 | −$9.04 | −$1.35 | −$0.95 | −$1.58 | — | −$31.04 | −$1.15 | −$1.34 |
| Balance sheet | ||||||||||
| Cash and equivalents | $10.00M | $1.60M | $12.4M | $4.91M | $6.25M | $5.58M | $2.12M | $9.80M | $94.9M | $97.6M |
| Total assets | $23.3M | $9.89M | $13.3M | $6.37M | $6.87M | $5.99M | $3.40M | $11.7M | $96.7M | $104.2M |
| Total liabilities | $6.20M | $1.01M | $1.57M | $2.59M | $2.24M | $1.75M | $1.91M | $3.59M | $4.69M | $7.16M |
| Shareholders' equity | $17.1M | $8.88M | $11.8M | $3.77M | $4.63M | $4.24M | $1.49M | $8.10M | $92.0M | $97.1M |
| Cash flow | ||||||||||
| Operating cash flow | −$15.9M | −$12.1M | −$5.50M | −$7.56M | −$9.27M | −$10.9M | −$11.4M | −$5.90M | −$14.8M | −$35.8M |
| Capital expenditure | $2.88K | $4.54K | $7.59K | $3.57K | $3.49K | $5.25K | $2.32K | — | — | — |
| Free cash flow | −$15.9M | −$12.1M | −$5.51M | −$7.56M | −$9.28M | −$10.9M | −$11.4M | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25†Jun 2025 | Q3 FY25†Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $0 | $0 | $0 | — | $0 | $0 |
| Operating income | −$4.62M | −$7.29M | −$11.3M | −$11.8M | −$16.8M | — | −$16.6M | −$18.8M |
| Net income | −$3.96M | −$6.27M | −$10.4M | −$10.8M | −$15.8M | — | −$15.7M | −$17.8M |
| EPS (diluted) | −$0.19 | $3.99 | −$0.28 | −$0.27 | −$0.40 | — | −$0.35 | −$0.35 |
| Balance sheet | ||||||||
| Cash and equivalents | $98.3M | $94.9M | $111.4M | $105.5M | $99.4M | $97.6M | $118.8M | $118.0M |
| Total assets | $99.8M | $96.7M | $112.1M | $105.9M | $102.8M | $104.2M | $123.2M | $121.7M |
| Total liabilities | $2.56M | $4.69M | $2.77M | $2.53M | $6.60M | $7.16M | $8.49M | $8.07M |
| Shareholders' equity | $97.2M | $92.0M | $109.3M | $103.3M | $96.2M | $97.1M | $114.7M | $113.6M |
| Cash flow | ||||||||
| Operating cash flow | −$3.09M | −$3.53M | −$6.97M | −$6.26M | −$9.15M | — | −$9.31M | −$14.2M |
From Tenax Therapeutics's 10-K, 10-KT and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Tenax Therapeutics in our feed yet.